NasdaqGM:VCYT
NasdaqGM:VCYTBiotechs

Veracyte (VCYT) Valuation Check After Strong Q3 Beat and Upgraded 2024 Revenue, Margin Guidance

Veracyte (VCYT) just delivered a stronger than expected third quarter, topping earnings and revenue forecasts and lifting its full year revenue and adjusted EBITDA margin guidance, a combination that tends to reset investor expectations fast. See our latest analysis for Veracyte. That upbeat guidance lands after a strong run, with the share price up around 37 percent on a 90 day basis and supported by a 67 percent three year total shareholder return. This suggests momentum is building even...
TSX:DSG
TSX:DSGSoftware

Does Descartes Systems Group’s (TSX:DSG) New Buyback Reveal a Deeper Shift in Capital Priorities?

Descartes Systems Group recently reported higher third-quarter and nine-month results to October 31, 2025, with sales and net income rising year-on-year, and then announced a new 12‑month share repurchase program subject to Toronto Stock Exchange approval. This combination of improving profitability and a planned buyback suggests management is prioritizing earnings quality and capital returns alongside continued growth investments. We’ll now explore how Descartes’ stronger earnings and...